Interpace Biosciences Inc
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $9.0M | $9.2M | $8.8M | $9.2M | $11.5M | $12.4M | $12.3M |
| Cost of Revenue | $3.5M | $3.1M | $3.2M | $3.3M | $4.0M | $4.1M | $4.5M | $4.4M |
| Gross Profit | $5.7M | $5.9M | $6.0M | $5.4M | $5.3M | $7.4M | $7.9M | $7.9M |
| Gross Margin | 61.9% | 65.4% | 65.5% | 62.1% | 57.1% | 64.0% | 63.7% | 64.3% |
| Operating Expenses | ||||||||
| Research & Development | $149.0K | $153.0K | $142.0K | $150.0K | $173.0K | $177.0K | $194.0K | $199.0K |
| SG&A Expense | $3.0M | $2.5M | $2.2M | $2.1M | $2.7M | $2.6M | $2.6M | $2.5M |
| Operating Income | $321.0K | $1.1M | $1.6M | $1.1M | $-468.0K | $1.8M | $2.1M | $2.3M |
| Operating Margin | 3.5% | 12.4% | 17.1% | 13.1% | -5.1% | 15.9% | 16.6% | 18.7% |
| Interest Expense | — | — | — | $30.0K | $49.0K | $78.0K | — | $141.0K |
| Pretax Income | $330.0K | $1.1M | $1.5M | $1.0M | $-533.0K | $1.8M | $1.9M | $1.8M |
| Income Tax Expense | $64.0K | $302.0K | — | $-11.0K | — | $18.0K | $-8.0K | $4.0K |
| Net Income | $158.0K | $721.0K | $22.7M | $911.0K | $-640.0K | $1.6M | $1.9M | $1.7M |
| Net Margin | 1.7% | 8.0% | 245.6% | 10.4% | -6.9% | 14.3% | 15.2% | 13.6% |
| EPS (Basic) | $0.01 | $0.03 | $5.11 | $0.21 | $-0.14 | $0.37 | $0.32 | $0.10 |
| EPS (Diluted) | $0.01 | $0.03 | $0.94 | $0.03 | $-0.14 | $0.06 | $-0.69 | $0.10 |
| Shares Outstanding (Basic) | 27.7M | 22.8M | 4.4M | 4.4M | 4.4M | 4.4M | 4.4M | 17.6M |
| Shares Outstanding (Diluted) | 27.7M | 27.7M | 27.7M | 27.7M | 4.4M | 27.7M | 15.7M | 17.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |